君实“特瑞普利单抗”:获得FDA突破性疗法认定的国产PD-1

2020-09-10 向雪 亿欧

今日,君实生物发布公告称,其“特瑞普利单抗注射液”用于鼻咽癌的治疗获得FDA突破性疗法认定,特瑞普利单抗成为首个获得FDA突破性疗法认定的国产抗PD-1单抗,这是继2020年5

今日,君实生物发布公告称,其“特瑞普利单抗注射液”用于鼻咽癌的治疗获得FDA突破性疗法认定,特瑞普利单抗成为首个获得FDA突破性疗法认定的国产抗PD-1单抗,这是继2020年5月特瑞普利单抗治疗鼻咽癌获得FDA孤儿药认定后又一重要注册进展。

公告称,本次特瑞普利单抗治疗鼻咽癌获得FDA突破性疗法认定能够显着地支持并加速该药物在美国的商业化开发计划。

突破性疗法,源于《美国食品和药物管理局安全及创新法案》(FDASIA)的规定,适用于治疗严重或危及生命的疾病且初步临床证据显示出显着优于现有疗法的药品,旨在加速该药品的开发和审评程序,是继快速通道、加速批准、优先审评之后,FDA又一重要的新药评审通道。根据规定,获得突破性药物疗法认定的药物开发过程将获得包括FDA高层官员在内的更加密切的指导及多种形式的支持,保障在最短时间内为患者提供新的治疗选择。

PD-1单抗不仅在单药使用上具有良好疗效,还能够与各种产品、治疗手段联合使用,商业前景广阔让诸多药企纷纷布局。弗若斯特沙利文分析,2018 年全球抗PD-1/PD-L1抑制剂市场规模已达到163亿美元,预计2023年将达到639亿美元。

特瑞普利单抗注射液是中国首个批准上市的以PD-1为靶点的国产单抗药物。自2016年初开始临床研发至今,特瑞普利单抗已在中、美等多国开展了覆盖十余个瘤种的30多项临床研究。

2018年12月,特瑞普利单抗注射液获得国家药品监督管理局有条件批准上市,用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。2020年4月,特瑞普利单抗注射液用于治疗既往接受过二线及以上系统治疗失败的复发╱转移鼻咽癌的新适应症上市申请获得国家药监局受理。该适应症的上市申请是全球首个抗PD-1单抗治疗复发/转移鼻咽癌的新药上市申请。除此之外,特瑞普利单抗注射液联合化疗作为复发或转移性鼻咽癌患者一线治疗方案的III期临床研究JUPITER-02研究(NCT03581786)已完成入组。

2020年5月,特瑞普利单抗注射液用于治疗既往接受过系统治疗的局部进展或转移性尿路上皮癌的新适应症上市申请获得国家药监局受理。2020年3月,特瑞普利单抗联合阿昔替尼治疗黏膜黑色素瘤获得FDA孤儿药资格认定。

目前,除了特瑞普利单抗这一核心产品之外,君实生物还拥有注射用重组人源化抗PCSK9单克隆抗体JS002、抗BLyS单克隆抗体UBP1213,以及全球首创的抗BTLA单克隆抗体TAB004/JS004。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-20 1de62615m51(暂无匿称)

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-11 1483c61am76暂无昵称

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-11 1483c61am76暂无昵称

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-12 ms3000001121456932

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2027423, encodeId=f3e8202e423f2, content=<a href='/topic/show?id=48b368e28ea' target=_blank style='color:#2F92EE;'>#瑞普利单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68728, encryptionId=48b368e28ea, topicName=瑞普利单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Nov 24 07:48:16 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886948, encodeId=6db588694859, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82241693220, createdName=1de62615m51(暂无匿称), createdTime=Sun Sep 20 21:47:27 CST 2020, time=2020-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884461, encodeId=69b388446123, content=就, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:37 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884460, encodeId=a5248844608f, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:35 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884783, encodeId=470e884e83db, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png;jsessionid=23017AF9A43E478B081BD06235BF844F, createdBy=e98c5416040, createdName=ms3000001121456932, createdTime=Sat Sep 12 16:49:12 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75538, encryptionId=75fbe553800, topicName=突破性疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eca12667393, createdName=zhwj, createdTime=Sat Sep 12 14:48:16 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884459, encodeId=88208844599d, content=哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c2e5279157, createdName=1483c61am76暂无昵称, createdTime=Fri Sep 11 09:01:32 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-11 1483c61am76暂无昵称

    0

相关资讯

Sci Rep:高CD3和ICOS及低TIM-3表达预测食管鳞状细胞癌切除后的生存率良好

CD3+ TIL和T细胞ICOS表达升高与良好的预后相关,而高TIM-3表达则提示预后不良。

免疫治疗耐药?新联合疗法,有望克服PD-1免疫疗法耐药

以PD-1抑制剂为代表的免疫疗法,极大改变了癌症治疗现状。让许多患者,甚至是生命垂危的患者受益。不过,免疫疗法仅适用于少数患者,许多患者无法从中获益,或是最终仍会经历癌症复发。

Nat Med:透明细胞肾细胞肿瘤中体细胞变异和免疫浸润互作调控对PD-1阻断的响应

PD-1阻断革新了对晚期透明细胞肾细胞癌(ccRCC)的治疗,但是PD-1响应的驱使因子和抵抗因子仍旧不完全清晰。

三大国产PD-1首年业绩PK,均在10亿元

信达生物3月30日晚披露2019年业绩。PD-1信利迪单抗销售额10亿人民币,毛利率88%。至此,三家国产PD-1企业财报均已披露。同时,2020年4月23日,信达生物发布公告,PD-1抗体(信迪利单

KSQ Therapeutics发现潜在活性优于PD-1的基因靶标,可用于开发针对性的工程化肿瘤浸润淋巴细胞(eTIL)治疗难治性实体瘤

生物技术公司KSQ Therapeutics使用其专有的CRISPRomics发现平台来系统筛选整个基因组,以鉴定肿瘤学和自身免疫性疾病的最佳基因靶标,今天宣布新型靶标CT-1可开发用于工程化肿瘤浸润淋巴细胞(eTIL?)治疗难治性实体瘤。

针对PD-1和CTLA-4之外的新型免疫检查点抑制剂VISTA,Curis收购抗VISTA抗体并准备将其商业化

美国生物科技公司Curis今天宣布已从ImmuNext 公司获得治疗癌症的抗VISTA单抗CI-8993的全球独家权利。CI-8993是临床阶段的单克隆抗体,旨在拮抗抑制T细胞活化的V域(VISTA)信号通路。